Wednesday, July 8, 2026

biotech · Uveal Melanoma · Choroidal Melanoma · AURA

Aura Biosciences

Aura Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker AURA. Primary therapeutic focus areas include Uveal Melanoma, Choroidal Melanoma, Primary Indeterminate Lesions or S

Boston, USA HQ
2009 Founded
128 Employees
Public company Type
AURA · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2009
Employees
128
Programs
6
Drugs
3
Patents
17
Clinical program

Bel-sar

Phase 3 · small molecule · Choroidal Melanoma

Bel-sar for Choroidal Melanoma is a Phase 3 program (small_molecule) at Aura Biosciences with 1 ClinicalTrials.gov record(s).

← All Aura Biosciences projects Phase 3 small molecule active

Internal code AU-011-301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Aura Biosciences
Phase
Phase 3
Modality
small_molecule
Indication
Choroidal Melanoma
Status
active
Trials
1

Clinical trials